1-5 of 5
Manuela Tosi, BiolSc
Close
Sort by
Journal Articles

Next Generation Sequencing (NGS) of TP53 Gene Allows to Identify a Very High Risk Group of Philadelphia Negative Acute Lymphoblastic Leukemia (ALL) Patients

Silvia Salmoiraghi, BiolSc, Greta Ubiali, BiolSc, Manuela Tosi, BiolSc, Barbara Peruta, BiolSc, Marie Lorena Guinea Montalvo, BiolSc, Elena Oldani, BiolSc, Cristina Boschini, MSc, Alexander Kohlmann, PhD, Sabina Chiaretti, Tamara Intermesoli, MD, Renato Bassan, MD, Orietta Spinelli, PhD, Alessandro Rambaldi
Journal: Blood
Blood (2014) 124 (21): 3796.
https://doi.org/10.1182/blood.V124.21.3796.3796
Published: 2014
Journal Articles

Phase II Randomized Trial Of Radiation-Free Central Nervous System (CNS) Prophylaxis Comparing Intrathecal Triple Therapy With Liposomal Cytarabine (DepoCyte ® ) In Adult Acute Lymphoblastic Leukemia (ALL)

Renato Bassan, MD, Arianna Masciulli, BiolSc, Tamara Intermesoli, MD, Ernesta Audisio, MD, Chiara Cattaneo, MD, Enrico Maria Pogliani, MD, Vincenzo Cassibba, MD, Daniele Mattei, MD, Claudio Romani, MD, Agostino Cortelezzi, MD, Consuelo Corti, MD, Anna Maria Scattolin, MD, Orietta Spinelli, BiolSC, Manuela Tosi, BiolSC, Margherita Parolini, MD, Filippo Marmont, MD, Erika Borlenghi, MD, Monica Fumagalli, MD, Sergio Cortelazzo, MD, Andrea Gallamini, MD, Rosa Maria Marfisi, Elena Oldani, BiolSC, Roberto Marchioli, MD, Alessandro Rambaldi, MD
Journal: Blood
Blood (2013) 122 (21): 3901.
https://doi.org/10.1182/blood.V122.21.3901.3901
Published: 2013
Journal Articles

In Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Imatinib (IM) and Chemotherapy in Combination Improve Remission Rate, Stem Cell Transplantation Rate and Long-Term Outcome

Tamara Intermesoli, MD, Chiara Cattaneo, MD, Enrico Maria Pogliani, MD, Eros Di Bona, MD, Claudio Romani, MD, Vincenzo Cassibba, MD, Agostino Cortelezzi, MD, Francesco Mannelli, MD, Fabio Ciceri, MD, Daniele Mattei, MD, Orietta Spinelli, BiolSC, Manuela Tosi, BiolSC, Elena Oldani, BiolSC, Alessandro Rambaldi, MD, Renato Bassan, MD
Journal: Blood
Blood (2012) 120 (21): 662.
https://doi.org/10.1182/blood.V120.21.662.662
Published: 2012
Journal Articles

Early Response Dynamics Including Minimal Residual Disease (MRD) and Adherence to Risk/MRD-Oriented Therapy Are Major Outcome Determinants in Adult Ph-Negative Acute Lymphoblastic Leukemia (ALL).

Renato Bassan, MD, Orietta Spinelli, BiolSC, Elena Oldani, BiolSC, Manuela Tosi, BiolSC, Barbara Peruta, BiolSC, Erika Borlenghi, MD, Enrico Maria Pogliani, MD, Eros Di Bona, MD, Vincenzo Cassibba, MD, Anna Maria Scattolin, MD, Claudio Romani, MD, Fabio Ciceri, MD, Agostino Cortelezzi, MD, Giacomo Gianfaldoni, MD, Daniele Mattei, MD, Ernesta Audisio, MD, Tamara Intermesoli, Alessandro Rambaldi, MD
Journal: Blood
Blood (2012) 120 (21): 2573.
https://doi.org/10.1182/blood.V120.21.2573.2573
Published: 2012
Journal Articles

In Adult Acute Lymphoblastic Leukemia (ALL) Different Minimal Residual Disease (MRD) Levels Predict Clinical Outcome in All Patients and Response to Allogeneic/Autologous Transplantation in MRD-Positive Patients.

Renato Bassan, MD, Orietta Spinelli, BiolSC, Elena Oldani, BiolSC, Manuela Tosi, BiolSC, Barbara Peruta, BiolSC, Erika Borlenghi, MD, Enrico Maria Pogliani, MD, Eros Di Bona, MD, Vincenzo Cassibba, MD, Anna Maria Scattolin, MD, Claudio Romani, MD, Fabio Ciceri, MD, Agostino Cortelezzi, MD, Giacomo Gianfaldoni, MD, Daniele Mattei, MD, Ernesta Audisio, MD, Tamara Intermesoli, Alessandro Rambaldi, MD
Journal: Blood
Blood (2012) 120 (21): 2493.
https://doi.org/10.1182/blood.V120.21.2493.2493
Published: 2012